Alzheimer's Disease:
Prevention and New Treatments

1. What Is Alzheimer's Disease?

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the gradual and irreversible loss of neurons, primarily in brain regions responsible for memory, language, and executive function. First described by German psychiatrist Alois Alzheimer in 1906 after examining the brain of a patient named Auguste Deter, the disease remains the most common cause of dementia in the elderly population worldwide.

Unlike normal age-related forgetfulness, Alzheimer's involves a pathological cascade of events that leads to widespread neuronal death. The disease typically begins in the entorhinal cortex and hippocampus — brain structures critical for forming new memories — before spreading to the temporal, parietal, and eventually frontal lobes. This progressive anatomical involvement explains why early symptoms center on memory, while later stages affect language, visuospatial skills, personality, and basic motor functions.

Alzheimer's disease is classified into two main forms: early-onset AD (before age 65, representing fewer than 5% of cases, often linked to autosomal dominant mutations in APP, PSEN1, or PSEN2 genes) and late-onset AD (after age 65, the vast majority of cases, driven by a complex interplay of genetic susceptibility — particularly the APOE ε4 allele — environmental factors, and aging). Understanding the distinction between these forms is crucial for genetic counseling and research stratification.

2. Pathophysiology: The Amyloid Cascade and Tau Tangles

The hallmark pathological features of Alzheimer's disease are extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. These two proteinopathies form the foundation of the amyloid cascade hypothesis, which has dominated AD research for over three decades.

The amyloid cascade hypothesis proposes that the disease is initiated by the abnormal cleavage of the amyloid precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase enzymes. This process generates Aβ42 peptides that are prone to aggregation. These peptides oligomerize into soluble toxic species and eventually deposit as insoluble fibrillary plaques in the brain parenchyma. Soluble Aβ oligomers are now considered the most neurotoxic species, disrupting synaptic function, triggering inflammatory cascades, and promoting oxidative stress long before plaques become visible on imaging.

Tau protein normally stabilizes microtubules within axons, supporting intracellular transport. In Alzheimer's, tau becomes hyperphosphorylated, detaches from microtubules, and aggregates into paired helical filaments that form neurofibrillary tangles. Tau pathology correlates more closely with cognitive decline than amyloid plaque burden, following a stereotypical spread pattern described by Braak staging (stages I–VI), from the transentorhinal cortex to the neocortex.

Beyond amyloid and tau, contemporary research has identified additional pathogenic mechanisms including neuroinflammation (microglial activation and complement system dysregulation), vascular dysfunction (blood-brain barrier breakdown), mitochondrial impairment, synaptic loss, and impaired glymphatic clearance during sleep. The disease is now understood as a multifactorial process rather than a simple linear cascade.

3. Modifiable Risk Factors

A landmark report by the Lancet Commission on Dementia Prevention, Intervention, and Care (2020) identified 12 modifiable risk factors that together account for approximately 40% of all dementia cases worldwide. This means that a substantial proportion of Alzheimer's cases could theoretically be prevented or delayed through targeted interventions across the life course.

• Low educational attainment (early life) — limited cognitive reserve reduces resilience to neuropathology
• Hearing loss (midlife) — the single largest modifiable risk factor, contributing ~8% of attributable risk; leads to social isolation and reduced cognitive stimulation
• Traumatic brain injury (midlife) — repeated head trauma, including subconcussive impacts, accelerates amyloid and tau deposition
• Hypertension (midlife) — uncontrolled blood pressure damages cerebral vasculature and promotes white matter lesions
• Excessive alcohol consumption (midlife) — more than 21 units per week increases dementia risk through direct neurotoxicity and thiamine deficiency
• Obesity (midlife) — adiposity promotes systemic inflammation, insulin resistance, and cerebrovascular disease
• Smoking (later life) — accelerates vascular damage and oxidative stress in the brain
• Depression (later life) — chronic depression elevates cortisol, reduces hippocampal volume, and may represent a prodromal symptom
• Social isolation (later life) — lack of social engagement reduces cognitive reserve and is associated with increased amyloid burden
• Physical inactivity (later life) — sedentary behavior reduces cerebral blood flow, BDNF expression, and neurogenesis
• Diabetes mellitus (later life) — insulin resistance in the brain impairs Aβ clearance; type 2 diabetes doubles dementia risk
• Air pollution (later life) — fine particulate matter (PM2.5) triggers neuroinflammation and accelerates cognitive decline

4. Early Signs and Symptoms

Recognizing the early signs of Alzheimer's disease is critical for timely intervention. The Alzheimer's Association has identified ten warning signs that distinguish pathological cognitive decline from normal aging:

• Memory loss that disrupts daily life — forgetting recently learned information, important dates, or events; repeatedly asking the same questions
• Challenges in planning or problem-solving — difficulty following a familiar recipe, managing monthly bills, or concentrating on tasks
• Difficulty completing familiar tasks — trouble driving to a known location, organizing a grocery list, or remembering rules of a favorite game
• Confusion with time or place — losing track of dates, seasons, or the passage of time; forgetting where they are or how they got there
• Trouble understanding visual and spatial relationships — difficulty reading, judging distance, or determining color and contrast
• New problems with words — trouble following or joining conversations; struggling with vocabulary or calling things by the wrong name
• Misplacing things — putting items in unusual places and being unable to retrace steps; may accuse others of stealing
• Decreased or poor judgment — giving large sums to telemarketers, paying less attention to grooming, or making poor financial decisions
• Withdrawal from activities — removing themselves from hobbies, social activities, or work projects they previously enjoyed
• Changes in mood and personality — becoming confused, suspicious, depressed, fearful, or anxious; easily upset in unfamiliar settings

The clinical stage between normal aging and dementia is called Mild Cognitive Impairment (MCI). Individuals with MCI due to Alzheimer's show measurable cognitive deficits (particularly in episodic memory) but can still function independently. Approximately 10–15% of MCI patients progress to dementia annually, making this a critical window for intervention.

5. Diagnosis: Biomarkers and the AT(N) Framework

The diagnosis of Alzheimer's disease has evolved dramatically from a purely clinical assessment to a biomarker-driven framework. In 2018, the National Institute on Aging and the Alzheimer's Association (NIA-AA) introduced the AT(N) classification, which defines Alzheimer's by its biological hallmarks rather than clinical symptoms alone:

A landmark advance has been the development of blood-based biomarkers. Plasma p-tau217 has demonstrated over 90% accuracy in distinguishing Alzheimer's from other dementias in multiple validation studies, potentially transforming diagnosis from expensive PET scans and invasive lumbar punctures to a simple blood test. The PrecivityAD2 test (measuring plasma p-tau217 and Aβ42/40) received clinical use designation in 2024 and is expected to become a standard screening tool in primary care settings.

Structural MRI remains essential for ruling out other causes of cognitive decline (brain tumors, normal pressure hydrocephalus, vascular lesions) and for documenting medial temporal lobe atrophy — a radiological hallmark of AD. Volumetric analysis of the hippocampus is increasingly automated and used for tracking disease progression in clinical trials.

6. New Treatments: Lecanemab, Donanemab, and Beyond

After decades of clinical trial failures, the field of Alzheimer's therapeutics entered a new era with the approval of anti-amyloid monoclonal antibodies. These drugs represent the first disease-modifying treatments — therapies that target the underlying pathology rather than merely managing symptoms.

Lecanemab (Leqembi®)

Lecanemab is a humanized IgG1 monoclonal antibody that selectively targets soluble Aβ protofibrils — the most toxic amyloid species. The pivotal CLARITY AD trial (van Dyck et al., NEJM 2023) enrolled 1,795 participants with early-stage AD and demonstrated that lecanemab, administered as an intravenous infusion every two weeks, reduced clinical decline by 27% over 18 months as measured by the CDR-SB (Clinical Dementia Rating — Sum of Boxes). Brain amyloid burden was reduced by an average of 55–59 centiloids on PET imaging. The FDA granted full approval to lecanemab in July 2023.

The main safety concern is amyloid-related imaging abnormalities (ARIA), which include ARIA-E (edema/effusions, occurring in ~13% of participants) and ARIA-H (microhemorrhages, in ~17%). Most ARIA events were asymptomatic or mild, but the risk is significantly higher in APOE ε4 homozygous carriers (~36% ARIA-E rate), requiring careful genotyping before initiation and regular MRI monitoring.

Donanemab (Kisunla™)

Donanemab is a humanized IgG1 antibody that targets a modified form of deposited Aβ (N3pG-Aβ), binding directly to amyloid plaques. The TRAILBLAZER-ALZ 2 trial (Sims et al., JAMA 2023) enrolled 1,736 participants with early symptomatic AD and showed a 35% slowing of decline on the iADRS (integrated Alzheimer's Disease Rating Scale) in the low/medium tau subgroup over 76 weeks. Remarkably, 47% of participants achieved amyloid-negative status (below 24.1 centiloids) by 12 months, allowing treatment discontinuation. The FDA approved donanemab in July 2024.

Beyond anti-amyloid antibodies, the pipeline includes therapies targeting tau aggregation (semorinemab, bepranemab), neuroinflammation (AL002, targeting TREM2 on microglia), synaptic resilience (CT1812, blocking Aβ oligomer binding to the sigma-2 receptor), and gene therapy approaches. The concept of combination therapy — addressing multiple pathological pathways simultaneously — is gaining traction, analogous to the multi-drug regimens used in oncology and HIV medicine.

7. Lifestyle and Prevention: The FINGER Protocol

While pharmacotherapy advances, the strongest evidence for Alzheimer's risk reduction comes from multimodal lifestyle interventions. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), published in The Lancet in 2015, was the first large-scale randomized controlled trial to demonstrate that a multidomain intervention could improve or maintain cognitive function in at-risk older adults.

The FINGER protocol included four simultaneous components delivered over two years to 1,260 participants aged 60–77 with elevated dementia risk:

• Nutritional guidance — based on Finnish nutritional recommendations emphasizing fruits, vegetables, whole grains, lean protein, and rapeseed oil; limiting saturated fat, sugar, and salt (similar to the MIND diet)
• Physical exercise — progressive program of aerobic training (walking, jogging, aqua gym), resistance training (1–3 sessions/week), and postural balance exercises; supervised by physiotherapists
• Cognitive training — computer-based exercises targeting executive function, processing speed, and episodic memory; group sessions on age-related cognitive changes and compensatory strategies
• Vascular risk monitoring — regular assessment and management of blood pressure, BMI, blood glucose, and lipid profiles; medication adjustment when needed in collaboration with primary care

After two years, the intervention group showed a 25% improvement in overall cognition compared to the control group, with the largest benefits in executive function (83% improvement) and processing speed (150% improvement). The study spawned the World-Wide FINGERS network, now replicating the protocol across more than 40 countries.

The MIND Diet

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) was developed by Martha Clare Morris at Rush University and combines elements of the Mediterranean and DASH diets specifically optimized for brain health. Observational data suggests that strict adherence reduces Alzheimer's risk by up to 53%, while even moderate adherence reduces risk by approximately 35%. The diet emphasizes ten brain-healthy food groups (green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil, and wine in moderation) and limits five groups (red meat, butter/margarine, cheese, pastries/sweets, and fried/fast food).

Exercise as Neuroprotection

Physical activity is perhaps the single most powerful modifiable factor for brain health. Aerobic exercise increases brain-derived neurotrophic factor (BDNF), promotes hippocampal neurogenesis, enhances cerebral blood flow, reduces neuroinflammation, and improves insulin sensitivity in the brain. A meta-analysis by Northey et al. (British Journal of Sports Medicine, 2018) found that exercise interventions of at least 45 minutes of moderate-to-vigorous intensity, performed on most days of the week, significantly improve cognitive function in adults over 50 regardless of baseline cognitive status.

8. Caregiver Support and Resources

Alzheimer's disease does not affect only the patient — it profoundly impacts families and caregivers. In the United States, more than 11 million people provide unpaid care for someone with Alzheimer's or another dementia, contributing an estimated 18 billion hours of care valued at nearly $340 billion annually. Caregivers of people with dementia experience higher rates of depression, anxiety, chronic stress, and physical illness compared to non-caregivers.

The concept of caregiver burden encompasses physical exhaustion, emotional distress, social isolation, financial strain, and a sense of loss as the person they knew gradually changes. Studies show that 30–40% of dementia caregivers meet criteria for clinical depression, and the chronic stress of caregiving has been associated with increased inflammatory markers, impaired immune function, and even accelerated telomere shortening.

Evidence-based strategies for caregiver support include:

• Psychoeducation programs — structured courses that teach caregivers about the disease, behavioral management techniques, communication strategies, and self-care. Programs such as REACH II and the NYU Caregiver Intervention have shown significant reductions in caregiver depression and delayed nursing home placement.
• Respite care — temporary relief through adult day programs, in-home aides, or short-term residential care. Regular respite reduces burnout and improves caregiver well-being.
• Support groups — peer-led or facilitated groups (in-person or virtual) provide emotional support, practical advice, and a sense of community. The Alzheimer's Association operates a 24/7 helpline (1-800-272-3900) and online support communities.
• Legal and financial planning — early establishment of power of attorney, advance directives, and long-term care planning while the patient retains decision-making capacity.
• Technology-assisted monitoring — GPS tracking devices, medication reminders, smart home sensors, and telehealth platforms can enhance safety and reduce caregiver anxiety without compromising patient autonomy.

As Alzheimer's progresses through moderate and severe stages, goals of care should be discussed openly with the family. Palliative care principles — focusing on comfort, dignity, and quality of life — become increasingly important. Advance care planning, including preferences for hospitalization, feeding tubes, and end-of-life care, should ideally be addressed while the patient can still participate in decisions.